Tamsulosin Hydrochloride Capsule
Product Images NDC 70518-2052

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 70518-2052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Tamsulosin HCI is a prescription medication in capsule form with a strength of 0.4 mg. The package contains 90 capsules and should be kept out of the reach of children. Directions for use are provided in the package insert. The medication should be stored within the temperature range of 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. The medication was repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.466.8762. The LOT # and expiry date are not available in the provided text.*

FDA Label Image

Tamsulosin HCl 0.4mg 70518 2052 01

Tamsulosin HCI is a medication that comes in capsules that contain 0.4mg. It is available in a package of 30 and requires a prescription to be acquired. The medication is manufactured by Aurcbindo in India and should be kept out of the reach of children. The lot number and NDC number are also provided on the package. Directions for use are provided in the package insert, and the medication should be stored at a temperature between 20-26°C, with excursions permitted to 15-30°C. The medication has been repackaged by RemedyRepack Inc. based in Indiana, PA.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

This is a figure showing the mean plasma concentration of Tamsulosin Hydrochloride following single-dose administration of Tamsulosin Hydrochloride Capsules 0.4 mg under fasted and fed conditions over a period of time in hours. There is no further information available.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

The figure shows the mean change from baseline in the total AUA symptom score on a scale of 0 to 35 for Study 1. The treatment groups included -OO-0-08mg_~A= A -A04my_ and O30 placebo. The duration of treatment was 758, 693, 665, 637, 619, and 616 weeks, respectively. Data for the mean change are presented at weeks 0, 1, 2, 4, 10, 13 using LOCF.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

Figure 2B shows the mean change from baseline in the total American Urological Association (AUA) symptom score (0 to 35) observed in Study 2. The treatment options included 0.08mg LNt, 0.4mg, and placebo. The study lasted for a duration of weeks represented in the X-axis. However, no information about the study results is provided.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

The description for this image is: "Mean Increase in Peak Urine Flow Rate (in L/Sec) Study 1" with a graph showing the treatment, mean change in mL/sec, and duration of treatment in weeks.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

The text is showing a figure related to a study that measures the mean increase in peak urine flow rate in mL/sec. It is labeled as Figure 3B and relates to Study 2. The figure displays different treatment durations in weeks and their corresponding values for the urine flow rate. There is additional text represented in the figure, but it cannot be evaluated due to errors.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.